130 related articles for article (PubMed ID: 34488517)
1. Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC).
Muszbek N; Evans R; Remak E; Brennan VK; Colaone F; Shergill S; Ross P; Mullan D
Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):147-154. PubMed ID: 34488517
[TBL] [Abstract][Full Text] [Related]
2. A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK.
Pollock RF; Colaone F; Guardiola L; Shergill S; Brennan VK
J Med Econ; 2020 Jun; 23(6):593-602. PubMed ID: 32067534
[No Abstract] [Full Text] [Related]
3. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P
J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
5. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma.
Muszbek N; Remak E; Evans R; Brennan VK; Colaone F; Shergill S; Mullan D; Ross PJ
Future Oncol; 2021 Mar; 17(9):1055-1068. PubMed ID: 33222542
[No Abstract] [Full Text] [Related]
7. NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with
Venerito M; Pech M; Canbay A; Donghia R; Guerra V; Chatellier G; Pereira H; Gandhi M; Malfertheiner P; Chow PKH; Vilgrain V; Ricke J; Leandro G
J Nucl Med; 2020 Dec; 61(12):1736-1742. PubMed ID: 32358087
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of one month imaging following selective internal radiation therapy.
Young S; Taylor A; Golzarian J; Flanagan S; D'Souza D; Sanghvi T
Diagn Interv Imaging; 2019 Jan; 100(1):39-46. PubMed ID: 30082184
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma.
Marqueen KE; Kim E; Ang C; Mazumdar M; Buckstein M; Ferket BS
JCO Oncol Pract; 2021 Feb; 17(2):e266-e277. PubMed ID: 33417490
[TBL] [Abstract][Full Text] [Related]
10. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
11. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
Edeline J; Crouzet L; Campillo-Gimenez B; Rolland Y; Pracht M; Guillygomarc'h A; Boudjema K; Lenoir L; Adhoute X; Rohou T; Boucher E; Clément B; Blanc JF; Garin E
Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):635-43. PubMed ID: 26455499
[TBL] [Abstract][Full Text] [Related]
12. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review.
Lee EW; Alanis L; Cho SK; Saab S
Korean J Radiol; 2016; 17(4):472-88. PubMed ID: 27390539
[TBL] [Abstract][Full Text] [Related]
13. A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization.
Weng Z; Ertle J; Zheng S; Lauenstein T; Mueller S; Bockisch A; Gerken G; Yang D; Schlaak JF
PLoS One; 2013; 8(12):e82225. PubMed ID: 24367506
[TBL] [Abstract][Full Text] [Related]
14. Combined Yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: From clinical aspects to dosimetry.
Wang TH; Huang PI; Hu YW; Lin KH; Liu CS; Lin YY; Liu CA; Tseng HS; Liu YM; Lee RC
PLoS One; 2018; 13(1):e0190098. PubMed ID: 29293557
[TBL] [Abstract][Full Text] [Related]
15. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
[TBL] [Abstract][Full Text] [Related]
16. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
17. Advances in Delivery of Selective Internal Radiation Therapy (SIRT): Economic and Logistical Effects of Same-Stay Work-Up and Procedure in the Treatment of Unresectable Liver Tumors in England.
Pollock RF; Shergill S; Carion PL; von Oppen N; Agirrezabal I; Brennan VK
Adv Ther; 2023 Jan; 40(1):294-309. PubMed ID: 36318388
[TBL] [Abstract][Full Text] [Related]
18. Current role of selective internal radiation with yttrium-90 in liver tumors.
Lau WY; Teoh YL; Win KM; Lee RC; de Villa VH; Kim YH; Liang PC; Santos-Ocampo RS; Lo RH; Lim KB; Tai DW; Ng DC; Irani FG; Gogna A; Chow PK
Future Oncol; 2016 May; 12(9):1193-204. PubMed ID: 27007495
[TBL] [Abstract][Full Text] [Related]
19. SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study).
Hirsch RD; Mills C; Sawhney R; Sood S; Bird V; Mishra G; Dev A; Kemp W; Lubel J; Roberts SK; Gow P; Nicoll AJ
J Gastrointest Cancer; 2021 Sep; 52(3):907-914. PubMed ID: 32901445
[TBL] [Abstract][Full Text] [Related]
20. Catheter-Directed Computed Tomography Hepatic Angiography for Yttrium-90 Selective Internal Radiotherapy of Hepatocellular Carcinoma Reduces Prophylactic Embolization of Extrahepatic Vessels.
Goh WXT; Leong S; Too CW; Cheng LT; Saffari SE; Lee RZ; Ng STS; Lo RHG; Tay KH; Chan SXJM; Gogna A; Irani FG; Venkatanarasimha N; Loke KSH; Chow PKH; Ng DCE; Urlings TAJ; Patel A; Damodharan K; Toh LHW; Tan BS
Cardiovasc Intervent Radiol; 2020 Mar; 43(3):478-487. PubMed ID: 31705243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
